Literature DB >> 12516381

Facial paralysis caused by malignant skull base neoplasms.

Sam J Marzo1, John P Leonetti, Guy Petruzzelli.   

Abstract

OBJECT: Bell palsy remains the most common cause of facial paralysis. Unfortunately, this term is often erroneously applied to all cases of facial paralysis.
METHODS: The authors performed a retrospective review of data obtained in 11 patients who were treated at a university-based referral practice between July 1988 and September 2001 and who presented with acute facial nerve paralysis mimicking Bell palsy. All patients were subsequently found to harbor an occult skull base neoplasm. A delay in diagnosis was demonstrated in all cases. Seven patients died of their disease, and four patients are currently free of disease.
CONCLUSIONS: Although Bell palsy remains the most common cause of peripheral facial nerve paralysis, patients in whom neoplasms invade the facial nerve may present with acute paralysis mimicking Bell palsy that fails to resolve. Delays in diagnosis and treatment in such cases may result in increased rates of mortality and morbidity.

Entities:  

Mesh:

Year:  2002        PMID: 12516381

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  3 in total

1.  Metastatic Salivary Ductal Carcinoma to the Mastoid Segment of the Facial Nerve.

Authors:  Joshua E Fabie; Jonathan L Hatch; Ashley W Cross; Samuel L Oyer; David M Neskey; Theodore R McRackan
Journal:  Otol Neurotol       Date:  2018-09       Impact factor: 2.311

2.  Facial Palsy, Radiographic and Other Workup Negative: FROWN.

Authors:  Jacqueline J Greene; Reza Sadjadi; Nate Jowett; Tessa Hadlock
Journal:  Neurol Clin Pract       Date:  2021-10

3.  Clinical practice guidelines in idiopathic facial paralysis: systematic review using the appraisal of guidelines for research and evaluation (AGREE II) instrument.

Authors:  Neil N Luu; Kevin T Chorath; Brandon R May; Nuvid Bhuiyan; Alvaro G Moreira; Karthik Rajasekaran
Journal:  J Neurol       Date:  2021-01-03       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.